Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
about
Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse modelOverexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
P2860
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 April 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
@en
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
@nl
type
label
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
@en
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
@nl
prefLabel
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
@en
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
@nl
P2093
P2860
P1476
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
@en
P2093
Antoine Italiano
Audrey Laroche
Carlo Lucchesi
Christophe Rey
François Le Loarer
Kevin Tran
Marie-Paule Algéo
Vanessa Chaire
P2860
P2888
P356
10.1186/S13045-017-0451-X
P577
2017-04-11T00:00:00Z
P6179
1084737946